DeBeurs.nl

[verwijderd] 13 februari 2019 22:36

0

Misschien gaan we argenix wel achterna..... wonderen zijn de wereld nog niet uit.....!

Zo gaat dat 14 februari 2019 07:44

0

quote:
stoppelbaard schreef op 13 februari 2019 13:36:
....Wie heeft hier een goed advies maw wat suggereren we Dhr Groen, hijzelf zal niet spontaan opstappen lijkt me. Gewoon bijkopen en wachten op beter lijkt me ook geen goed Idee, Maar komt hier ooit nog verbetering (met het huidige potentieel van het bedrijf)? alvast bedankt voor jullie gedachten

Het rekenmodel van BassieNL heeft bij mij enkele maanden geleden de ogen geopend. Ook de opmerkingen van DWB sneden en snijden hout (wel een beetje veel herhaald ;-)). Dankzij deze heren is mijn verlies beperkt gebleven.

Toekomstbeeld van MDX is echt niet rooskleurig, er moet echt wel een wonder gebeuren willen ze de negatieve spiraal doorbreken.

Guus_Geluk 14 februari 2019 09:19

0

Wat is er aan de hand, is er nieuws? Flinke stijging met een flink volume.

Guus_Geluk 14 februari 2019 09:23

0

MDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada
NEWS RELEASE

IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, February 14, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announces that it has signed an exclusive distribution agreement with LifeLabs to make SelectMDx®, the Company's non-invasive liquid biopsy prostate cancer test, available in Canada. LifeLabs is a leading Canadian company that performs over 100 million laboratory tests per year to help diagnose, treat, monitor and prevent diseases, supporting over 19 million patient visits annually.

Under the terms of the partnership agreement, LifeLabs will serve as an exclusive distributor for SelectMDx in Canada. Liquid biopsy samples will be tested in MDxHealth's state-of-the-art clinical diagnostic laboratory in Irvine, California, and LifeLabs will reimburse MDxHealth for all testing services performed.

SelectMDx, the only non-invasive liquid biopsy diagnostic test available to selectively identify patients at increased risk of aggressive prostate cancer on the basis of two RNA urine biomarkers, has been shown to have a significant impact on initial prostate biopsy decision-making. Today, the standard of care to identify patients with prostate cancer is based on invasive, and often painful, prostate biopsies. However, these procedures are often inaccurate and unnecessary, with 80% of men undergoing a biopsy having no cancer detected, of which about 25% are expected to harbor indolent cancer missed by the procedure. .

In Canada, about 60,000 prostate biopsies are performed annually, resulting in about 24,000 newly diagnosed prostate cancer patients per year, while leaving about 1.4 million at-risk Canadian men living with increased prostate-specific-antigen (PSA) levels. The Canadian Cancer Society estimates that, by 2030, the number of patients diagnosed each year with prostate cancer will increase to 42,000 from 24,000 today, mainly driven by an ageing population and lifestyle.
"We are very excited to partner with MDxHealth and to provide SelectMDx to our customers across Canada," stated Charles Brown, CEO of LifeLabs. "By making this innovative, non-invasive test available, we are improving the quality of prostate cancer diagnosis and delivering healthier outcomes for Canadians."
"With over 25,000 US patients tested with SelectMDx to date, the test is clearly gaining momentum to become the standard of care in diagnosing patients with increased risk for aggressive prostate cancer," said Dr. Jan Groen CEO of MDxHealth. "This partnership agreement with LifeLabs demonstrates our commitment to making SelectMDx widely available in North America and to offering a valuable and accurate alternative for patients at risk for prostate cancer."

About SelectMDx® for Prostate Cancer
Of the nearly 2 million prostate biopsies performed each year, less than a third identify cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive liquid biopsy method to assess a patient's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby reducing healthcare costs. The test has been included in the 2018 European Association of Urology (EAU) clinical guidelines.

About LifeLabs
LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor, and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services essential for optimal outcomes in healthcare. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, supporting over 19 million patient visits annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by OMERS Infrastructure Management Inc. In addition to being the first community lab to conduct non-invasive prenatal testing in Canada, LifeLabs is the first lab to provide online appointment booking for patients, non-fasting protocols and secure, online access to lab results for patients.

About MDxHealth®
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

mdxhealth.com/press-release/mdxhealth...

Guus_Geluk 14 februari 2019 10:10

0

Wat is het rustig hier?

Sardirod 14 februari 2019 10:23

0

Freeze up?

Lijkt goed nieuws te zijn. Of moet de koers voor de cijfers nog wat gerepareerd worden?

Guus_Geluk 14 februari 2019 10:37

0

Piet Particulier is er inmiddels uit op de bodem. Tijd voor een flinke rebound!

Guus_Geluk 14 februari 2019 10:39

0

quote:
belle/liam schreef op 12 februari 2019 17:06:
Als Kempen als doel 2,00€ aangeeft lijkt mij dat ze dit onderzocht hebben. Kopen dus!!

Precies!

Tilburg013 14 februari 2019 10:47

0

quote:
Pelikapuntzak schreef op 12 februari 2019 15:56:
[...]

Tel uit uw winst...........

Die begint nu op te lopen :)

africa2 14 februari 2019 13:43

0

Van kempen moet verboden worden , ze maken bedrijven kapot . en pas op hier zit ook een adertje onder het gras.

Guus_Geluk 14 februari 2019 15:40

0

Al 4 keer het gemiddelde dagvolume, het gaat lekker zo.

BelgFre 15 februari 2019 09:01

0

Feb 15 (Reuters) - MDXHEALTH SA MDXH.BR :
* REG-MDXHEALTH (R): MDXHEALTH ANNOUNCES PRESENTATION OF
POSITIVE
DATA FOR SELECTMDX AND CONFIRMMDX IN PROSTATE CANCER DIAGNOSIS

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))

Guus_Geluk 15 februari 2019 09:11

0

Nou jongens, de rebound is begonnen. Zorg dat je erbij bent!

Guus_Geluk 15 februari 2019 09:22

0

quote:
BelgFre schreef op 15 februari 2019 09:01:
Feb 15 (Reuters) - MDXHEALTH SA MDXH.BR :
* REG-MDXHEALTH (R): MDXHEALTH ANNOUNCES PRESENTATION OF
POSITIVE
DATA FOR SELECTMDX AND CONFIRMMDX IN PROSTATE CANCER DIAGNOSIS

Source text for Eikon:
Further company coverage:

(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))

Piet Particulier is er uit op 1 euro, de rebound is begonnen!

[verwijderd] 15 februari 2019 09:30

0

Wat ben ik blij dat ik ze gehouden heb en nog extra heb bijgekocht onder de 1 euro. Eindelijk goed nieuws en snel richting de 2 euro.
succes, poil

Guus_Geluk 15 februari 2019 09:32

0

MDxHealth (R): MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis
NEWS RELEASE

Data to be Presented at the Annual ASCO Genitourinary Cancers Symposium

Data to further support clinical adoption of SelectMDx and ConfirmMDx

IRVINE, CA, and HERSTAL, BELGIUM - February 15, 2019 - MDxHealth SA (Euronext: MDXH.BR) today announced that positive data and observations from multiple studies and patient registries demonstrating the value of SelectMDx and ConfirmMDx for Prostate Cancer diagnosis, will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place in San Francisco, California, February 14-16, 2019.

The data, to be presented in four separate poster presentations, highlights:

Annual cost savings of nearly $500 million when SelectMDx is used prior to multi-parametric magnetic resonance imaging (mpMRI) for the identification of US patients at high risk for aggressive prostate cancer.
SelectMDx outperforms the Prostate Health Index (Phi) blood test for the detection of high-grade prostate cancer prior to tissue prostate biopsy.
Retrospective validation of SelectMDx in German patients confirms robust clinical performance.
Clinical utility study demonstrates that ConfirmMDx had a significant positive impact on repeat prostate biopsy decision-making.
"These new positive results from multiple studies with SelectMDx further strengthens our medical dossier and bring us an important step closer toward reimbursement and inclusion in clinical guidelines," stated Dr. Jan Groen, CEO of MDxHealth. "In addition, the completion and positive outcome from the second clinical utility study with ConfirmMDx will be of important value to further increase coverage, reimbursement and clinical adoption for this test." Dr. Groen concluded: "These results clearly demonstrate the superiority of our diagnostic tests and confirm our commitment to improving the lives of patients at high risk of aggressive prostate cancer by offering a valuable alternative for early and selective diagnosis of prostate cancer."

Further details of the studies can be found below. All abstracts were presented at the Poster Session entitled "Trials in Progress Poster Session: Prostate Cancer", on Thursday, February 14 from 11:30 AM-1:00 PM and 5:30-6:30 PM.

Abstract 91, Poster E15: Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer, First Author: Tim Govers, PhD
MRI is increasingly used in men with suspicion for prostate cancer (PCa) to target abnormal areas in addition to systematic biopsy. Although, MRI increases the detection of clinically significant PCa compared to systematic biopsy alone, overdiagnosis and overtreatment of insignificant disease still exists. A decision-analytic model was used to simulate downstream outcomes in the current MRI strategy. Using SelectMDx prior to MRI resulted in cost savings of $1,590 per patient and approximately $496 million annually for the US population of men at elevated risk of PCa. The use of SelectMDx to guide prostate biopsy decision-making can improve health outcomes and lower costs. Cost savings were highest when SelectMDx was used prior MRI to select patients for MRI and prostate tissue biopsy.

Abstract 30, Poster B18: SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer, First Author: Gretchen Hoyer
SelectMDx was compared with the Phi blood test (Beckman Coulter) for the diagnosis of high-grade PCa in a cohort of 80 patients undergoing transperineal mapping biopsy. Multivariate logistic regression showed that SelectMDx was significantly better than Phi for detecting high-grade PCa (B = 8.45, p = 0.0002). With its high sensitivity and high Negative Predictive Value (NPV), SelectMDx is more useful than Phi for screening patients at risk of high-grade PCa prior to tissue prostate biopsy.

Abstract 96, Poster E20: Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men, First Author: Derya Tilki, MD
SelectMDx was performed in a study population of 443 German men with an average age of 66 years who underwent initial prostate biopsy due to suspected PCa. The study showed that if SelectMDx would have been used prior biopsy, 46% of potentially unnecessary biopsies would have been avoided, while 5.8% of men with biopsy-detectable high-grade PCa (seven GG2 and one GG3) may have had their diagnosis too late. The clinical performance of SelectMDx was comparable to the published European validation study, showing a high NPV 95% (90-97%) for detection of GG2 or higher PCa. These results provide further evidence for the clinical validity of SelectMDx.

Abstract 94, Poster E18: Clinical utility study of ConfirmMDx for prostate cancer in a community urology practice, First Author: Paul Yonover, MD
The study population consisted of 605 men with a prior PCa-negative prostate biopsy, who were counseled on the need to undergo repeat biopsy at a large community urology practice due to persistent elevated risk of PCa. Of the 605 subjects enrolled, 308 (51%) had a negative ConfirmMDx test result and 297 (49%) were tested positive. In the entire study population, average age was 64 (median 64, interquartile range 59 to 69) and the average serum Prostate-Specific-Antigen (PSA) level was 6.8 ng/mL (5.7, 4.3 to 8.1). The median follow-up for both ConfirmMDx positives and negatives was 10 months post-testing. Repeat biopsy rates for ConfirmMDx positive and negative men were 32.3% (96/297) and 5.8% (15/308), respectively (P<0.001). ConfirmMDx had a significant impact on repeat prostate biopsy decision-making in a U.S. community urology setting. Repeat biopsy rates in ConfirmMDx positive men were six-fold higher than in ConfirmMDx negatives. These results reflect the clinical utility of ConfirmMDx for biopsy decision-making in real world clinical practice.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

MDxHealth

Dr. Jan Groen, CEO

US: +1 949 812 6979

BE: +32 4 257 70 21

info@mdxhealth.com

mdxhealth.com/press-release/mdxhealth...

JdeFL 15 februari 2019 09:33

0

Als ik zie hoe het nu bij oxurion gaat, zou die 1.25 die er nu staat, dicht bij het einde van de rebound kunnen zitten.

[verwijderd] 15 februari 2019 09:34

0

Een dag met een plus van 30-40%. Let maar op!
Groet, poil

Guus_Geluk 15 februari 2019 09:36

0

quote:
poil-1 schreef op 15 februari 2019 09:34:
Een dag met een plus van 30-40%. Let maar op!
Groet, poil

Bijna iedereen had het aandeel afgeschreven. Tja, en toen kwam er ineens heel goed nieuws naar buiten. Ik verwacht ook dat de 2 euro binnen no time weer op de borden komt te staan. Succes iedereen!

[verwijderd] 15 februari 2019 09:39

0

Stories

Therapy?

Get into the car and keep it down
City lights look like warnings now
She's got someone that pays for things
Trust me, she won't miss a thing

Come with me and believe me, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)

I get by on what I have
Less than Jesus, more than dad
Enough to keep me in this state
Ticking through to the next escape

Come with me and believe me, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)
Yeah, yeah
(Happy people have no stories)

I woke up late and I rolled the stone
Laziness and death in one
You were once a gentleman
Ended up a bitter man

Vertraagd	1 jan 0001
Koers	0,000
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	0

26 apr	Bioscoopketen AMC heeft last van Holl...
26 apr	Beursupdate: AEX op Wall Street	2
26 apr	Tech geeft Wall Street mooie impuls
26 apr	Porsche stelt teleur
26 apr	Olieprijzen stijgen licht
26 apr	Almunda handhaaft dividend
26 apr	Wall Street koerst flink hoger
26 apr	Europese beurzen positief het weekend in
26 apr	Slotcall: AEX met een knaller Konings...
26 apr	AEX sluit prima week positief af

MDxHealth « Terug naar discussie overzicht

MDX Health 2019

Meedoen aan de discussie?

Direct naar Forum

Detail

nieuws meer